1. Home
  2. BTAI
  3. BTAI News

Latest BioXcel Therapeutics Inc. (BTAI) News on December 19, 2024

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
BTAI

GlobeNewswire

a month ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

BioXcel Therapeutics Announces Proposed Public Offering
BTAI

GlobeNewswire

a month ago

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...
BTAI

GuruFocus.com

a month ago

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

BTAI

Thomson Reuters StreetEvents

a month ago

Q3 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
BTAI

Zacks

a month ago

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
BTAI

GlobeNewswire

a month ago

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings
BTAI

GuruFocus.com

a month ago

What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
BTAI

GlobeNewswire

a month ago

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
BTAI

GlobeNewswire

a month ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know
BTAI

Zacks

a month ago

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know

BioXcel Therapeutics to Present at ThinkEquity Conference
BTAI

GlobeNewswire

2 months ago

BioXcel Therapeutics to Present at ThinkEquity Conference

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
BTAI

GlobeNewswire

2 months ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
BTAI

GlobeNewswire

3 months ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares
BTAI

GuruFocus.com

3 months ago

FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BTAI

GlobeNewswire

3 months ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BTAI

Zacks

4 months ago

BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
BTAI

GlobeNewswire

4 months ago

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

BTAI

Thomson Reuters StreetEvents

4 months ago

Q2 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
BTAI

Zacks

4 months ago

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
BTAI

GlobeNewswire

4 months ago

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
BTAI

GlobeNewswire

5 months ago

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

BTAI

MT Newswires

5 months ago

BioXcel Therapeutics Shares Rise After Preliminary Q2 Revenue Exceeds Estimates

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
BTAI

GlobeNewswire

5 months ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
BTAI

GlobeNewswire

6 months ago

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024
BTAI

CNW Group

6 months ago

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge
BTAI

ACCESSWIRE

6 months ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies
BTAI

Business Insider

6 months ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
BTAI

GlobeNewswire

6 months ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger
BTAI

Motley Fool

6 months ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Unifor members vote to strike at Manitoba Hydro
BTAI

CNW Group

6 months ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly
BTAI

AFP

6 months ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires
BTAI

Business Insider

6 months ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
BTAI

GlobeNewswire

7 months ago

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
BTAI

GlobeNewswire

7 months ago

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
BTAI

Insider Monkey

7 months ago

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript

BioXcel Therapeutics First Quarter 2024 Earnings: Misses Expectations
BTAI

Simply Wall St.

7 months ago

BioXcel Therapeutics First Quarter 2024 Earnings: Misses Expectations

BTAI

Thomson Reuters StreetEvents

7 months ago

Q1 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics Reports First Quarter 2024 Financial Results
BTAI

GlobeNewswire

7 months ago

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
BTAI

GlobeNewswire

8 months ago

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
BTAI

GlobeNewswire

8 months ago

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
BTAI

GlobeNewswire

8 months ago

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
BTAI

GlobeNewswire

8 months ago

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

BioXcel Therapeutics Announces $25 Million Registered Direct Offering
BTAI

GlobeNewswire

9 months ago

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint
BTAI

Simply Wall St.

9 months ago

BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BTAI

GlobeNewswire

9 months ago

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
BTAI

Insider Monkey

9 months ago

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript

BTAI

Thomson Reuters StreetEvents

9 months ago

Q4 2023 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
BTAI

GlobeNewswire

9 months ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
BTAI

GlobeNewswire

10 months ago

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

15 Hot Penny Stocks On the Move
BTAI

Insider Monkey

10 months ago

15 Hot Penny Stocks On the Move

BioXcel Therapeutics Announces Termination of Proposed Public Offering
BTAI

GlobeNewswire

10 months ago

BioXcel Therapeutics Announces Termination of Proposed Public Offering

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
BTAI

GlobeNewswire

10 months ago

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

BioXcel Therapeutics Announces Proposed Public Offering
BTAI

GlobeNewswire

10 months ago

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
BTAI

GlobeNewswire

10 months ago

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
BTAI

GlobeNewswire

10 months ago

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

Baillie Gifford Bolsters Stake in American Superconductor Corp
BTAI

GuruFocus.com

a year ago

Baillie Gifford Bolsters Stake in American Superconductor Corp

Firms in Brazil Turn to Oracle for Security, Service, Speed
BTAI

Business Wire

a year ago

Firms in Brazil Turn to Oracle for Security, Service, Speed

Westwood Holdings Group, Inc. to Host Fourth Quarter and Fiscal Year 2023 Conference Call/Webcast
BTAI

GlobeNewswire

a year ago

Westwood Holdings Group, Inc. to Host Fourth Quarter and Fiscal Year 2023 Conference Call/Webcast

Chuck Royce Adjusts Position in Hurco Companies Inc
BTAI

GuruFocus.com

a year ago

Chuck Royce Adjusts Position in Hurco Companies Inc

BTAI

Newsfile

a year ago

Heritage Global, Inc. to Present at The Microcap Conference on Wednesday, January 31 and Thursday, February 1, 2024

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
BTAI

Zacks

a year ago

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Duluth Holdings Inc. Announces Appointment of Heena Agrawal as Chief Financial Officer
BTAI

GlobeNewswire

a year ago

Duluth Holdings Inc. Announces Appointment of Heena Agrawal as Chief Financial Officer

Best Momentum Stock to Buy for January 19th
BTAI

Zacks

a year ago

Best Momentum Stock to Buy for January 19th

LivePerson, Inc.'s (NASDAQ:LPSN) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures
BTAI

Simply Wall St.

a year ago

LivePerson, Inc.'s (NASDAQ:LPSN) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures

Spotting Winners: Noodles (NASDAQ:NDLS) And Modern Fast Food Stocks In Q3
BTAI

StockStory

a year ago

Spotting Winners: Noodles (NASDAQ:NDLS) And Modern Fast Food Stocks In Q3

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
BTAI

GlobeNewswire

a year ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Heritage Global, Inc. to Present at the Sequire Investor Summit in Puerto Rico
BTAI

GlobeNewswire

a year ago

Heritage Global, Inc. to Present at the Sequire Investor Summit in Puerto Rico

ASP Isotopes Inc. Provides Corporate Update
BTAI

GlobeNewswire

a year ago

ASP Isotopes Inc. Provides Corporate Update

Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
BTAI

GlobeNewswire

a year ago

Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics

LivePerson Names John Sabino as CEO
BTAI

PR Newswire

a year ago

LivePerson Names John Sabino as CEO

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
BTAI

GlobeNewswire

a year ago

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2024 Earnings Call Transcript
BTAI

Insider Monkey

a year ago

AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2024 Earnings Call Transcript

Amundi US Declares Monthly Distributions for Pioneer Closed-End Funds
BTAI

Business Wire

a year ago

Amundi US Declares Monthly Distributions for Pioneer Closed-End Funds

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
BTAI

GlobeNewswire

a year ago

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Burning Rock Announces Receipt of Notification from NASDAQ
BTAI

GlobeNewswire

a year ago

Burning Rock Announces Receipt of Notification from NASDAQ

Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
BTAI

Business Wire

a year ago

Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

Geospace Technologies Sells $30M in Ocean Bottom Nodes
BTAI

Business Wire

a year ago

Geospace Technologies Sells $30M in Ocean Bottom Nodes

Riverview Bancorp (NASDAQ:RVSB) Has Announced A Dividend Of $0.06
BTAI

Simply Wall St.

a year ago

Riverview Bancorp (NASDAQ:RVSB) Has Announced A Dividend Of $0.06

ALLIANCEBERNSTEIN NATIONAL MUNICIPAL INCOME FUND, INC. REPORTS FOURTH QUARTER EARNINGS
BTAI

PR Newswire

a year ago

ALLIANCEBERNSTEIN NATIONAL MUNICIPAL INCOME FUND, INC. REPORTS FOURTH QUARTER EARNINGS

Clarus Enters into Definitive Agreement to Sell Precision Sport Segment
BTAI

GlobeNewswire

a year ago

Clarus Enters into Definitive Agreement to Sell Precision Sport Segment

Chenghe Acquisition I Co. Receives Nasdaq Notice Regarding Late Form 10-Q Filings
BTAI

PR Newswire

a year ago

Chenghe Acquisition I Co. Receives Nasdaq Notice Regarding Late Form 10-Q Filings

Carter's (CRI) Continues to Focus on Pricing: Stock to Gain
BTAI

Zacks

a year ago

Carter's (CRI) Continues to Focus on Pricing: Stock to Gain

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
BTAI

GlobeNewswire

a year ago

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

City Office REIT Announces Dividends for Fourth Quarter 2023
BTAI

PR Newswire

a year ago

City Office REIT Announces Dividends for Fourth Quarter 2023

BTAI

PR Newswire

a year ago

JOHN HANCOCK CLOSED-END FUNDS ANNOUNCE RENEWAL OF SHARE REPURCHASE PLANS

Strength Seen in First Commonwealth Financial (FCF): Can Its 5.5% Jump Turn into More Strength?
BTAI

Zacks

a year ago

Strength Seen in First Commonwealth Financial (FCF): Can Its 5.5% Jump Turn into More Strength?

10 Best Bitcoin Stocks To Invest In
BTAI

Insider Monkey

a year ago

10 Best Bitcoin Stocks To Invest In

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

J.Jill, Inc. (NYSE:JILL) Q3 2023 Earnings Call Transcript
BTAI

Insider Monkey

a year ago

J.Jill, Inc. (NYSE:JILL) Q3 2023 Earnings Call Transcript

Skillsoft Reports Financial Results for the Third Quarter of Fiscal 2024
BTAI

Business Wire

a year ago

Skillsoft Reports Financial Results for the Third Quarter of Fiscal 2024

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
BTAI

Business Wire

a year ago

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

BTAI

PR Newswire

a year ago

JOHN HANCOCK CLOSED-END FUNDS DECLARE QUARTERLY DISTRIBUTIONS

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation
BTAI

Simply Wall St.

a year ago

Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation

7 Penny Stocks With Low Floats and High Short Interest
BTAI

InvestorPlace

a year ago

7 Penny Stocks With Low Floats and High Short Interest

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
BTAI

GlobeNewswire

a year ago

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

MVB Bank Named One of American Banker’s 2023 Best Banks to Work For
BTAI

Business Wire

a year ago

MVB Bank Named One of American Banker’s 2023 Best Banks to Work For

BTAI

Zacks Small Cap Research

a year ago

BTAI: Alignment with FDA on At-Home Study of BXCL501 in Alzheimer’s Agitation…

BioXcel Therapeutics Third Quarter 2023 Earnings: Misses Expectations
BTAI

Simply Wall St.

a year ago

BioXcel Therapeutics Third Quarter 2023 Earnings: Misses Expectations

Share on Social Networks: